Home2026March

Monthly Archives: March, 2026

IRBM reports progress in drug discovery for Zika virus

Louise Wilson-English -
IRBM, a leader in early drug discovery research, recently announced a major scientific breakthrough with the discovery of a new and potent allosteric inhibitor...

Sofetabart mipitecan receives ‘Breakthrough Therapy’ designation for the treatment of certain patients with platinum-resistant ovarian cancer

Louise Wilson-English -
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian,...

Preliminary AMT-191 phase 1/2a data shows sustained increases in α-Gal A enzyme activity in patients with Fabry Disease

Louise Wilson-English -
uniQure has announced updated preliminary safety and exploratory efficacy data from 11 patients in its phase 1/2a trial of AMT-191, an investigational AAV gene therapy...

Positive phase 3 topline results for oral infigratinib

Louise Wilson-English -
BridgeBio Pharma, a biopharmaceutical company focused on developing medicines for genetic conditions, has announced positive topline results from Propel 3, the global phase 3...

FDA removes barriers to cell, gene therapy development

Louise Wilson-English -
The FDA has said it will reduce the regulatory requirements on the manufacturing of cell and gene therapies (CGTs) in order to make it...

IRBM reports progress in drug discovery for Zika virus

Louise Wilson-English -
IRBM, a leader in early drug discovery research, recently announced a major scientific breakthrough with the discovery of a new and potent allosteric inhibitor...

Preclinical data published in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5)

Louise Wilson-English -
Lexicon Pharmaceuticals has announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The...

FDA grants approval for a gene therapy to treat rare genetic disease

Louise Wilson-English -
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the first therapy of its...

New results on NanoCas – an efficient ultracompact extrahepatic gene editor

Louise Wilson-English -
Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, has announced new preclinical research,...

Positive longer-term phase 1 data of Nexiguran Ziclumeran (nex-z) in patients with Transthyretin Amyloidosis with cardiomyopathy

Louise Wilson-English -
Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionising medicine with CRISPR-based therapies, has announced positive follow-up data from the ongoing phase 1 clinical...
12Page 1 of 2

Most Read